Meet Xeris Pharmaceuticals

Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.

Offering 2 proprietary formulation technologies

XeriSol XeriJect
Delivers highly concentrated, non-aqueous, ready-to-use formulations
Allows for subcutaneous (SC) and intramuscular (IM) delivery
Can be administered using:
  • Syringes
  • Single-use auto-injectors
  • Multidose pens
  • Infusion pumps
Delivers peptides and small molecules
Delivers large molecules (e.g., proteins, antibodies, vaccines)

XeriSol and XeriJect provide distinct advantages over existing formulations

Both XeriSol and XeriJect offer the opportunity to:

  • Eliminate reconstitution
  • Enable long-term room temperature stability
  • Significantly reduce injection volume
  • Eliminate the requirement for intravenous (IV) infusion

These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.

BACK
TO TOP